Investigating the role of Pluronic-g-Cationic polyelectrolyte as functional stabilizer for nanocrystals: Impact on Paclitaxel oral bioavailability and tumor growth

Acta Biomaterialia

Volumn 26, Issue , 2015, Pages 169-183

  Sharma, Shweta ^a   Verma, Ashwni ^a   Pandey, Gitu ^a   Mittapelly, Naresh ^a   Mishra, Prabhat Ranjan ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Chitosan; Murine melanoma; P gp efflux inhibition; Rhodamine 123; Taxol ; TEER

Indexed keywords

BIOCHEMISTRY; CHITOSAN; CONTROLLED DRUG DELIVERY; CYTOLOGY; DERMATOLOGY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; ONCOLOGY; PARTICLE SIZE; POLYELECTROLYTES; SUBSTRATES; TARGETED DRUG DELIVERY; TUMORS;

ANTICANCER DRUG; ELECTRICAL RESISTANCES; MURINE MELANOMA; P-GP EFFLUX INHIBITION; PACLITAXEL; PLURONICS; RHODAMINE 123; STABILISER; TAXOL™; TRANS EPITHELIAL ELECTRICAL RESISTANCE;

NANOCRYSTALS;

MULTIDRUG RESISTANCE PROTEIN; NANOCRYSTAL; PACLITAXEL; PLURONIC GRAFTED CHITOSAN COPOLYMER; POLOXAMER; POLYELECTROLYTE; RHODAMINE 123; STABILIZING AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ELECTROLYTE; EXCIPIENT; NANOCAPSULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACO 2 CELL LINE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TRANSPORT; ELECTRIC RESISTANCE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; TIGHT JUNCTION; TRANSEPITHELIAL ELECTRICAL RESISTANCE; ZETA POTENTIAL; ANIMAL; APOPTOSIS; BIOAVAILABILITY; BLOOD; CELL SURVIVAL; CHEMISTRY; CRYSTALLIZATION; DIFFUSION; DRUG EFFECTS; HUMAN; MOUSE; NEOPLASMS, EXPERIMENTAL; ORAL DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME; ULTRASTRUCTURE; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL SURVIVAL; CRYSTALLIZATION; DIFFUSION; ELECTROLYTES; EXCIPIENTS; HUMANS; MALE; MICE; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84942297303     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2015.08.005     Document Type: Article

References (72)

1. H. Chen, Y. Zheng, G. Tian, Y. Tian, X. Zeng, G. Liu, K. Liu, L. Li, Z. Li, L. Mei, and L. Huang Oral delivery of DMAB-modified Docetaxel-loaded PLGA-TPGS nanoparticles for cancer chemotherapy Nanoscale Res. Lett. 6 2010 1 10
2. E. Roger, S. Kalscheuer, A. Kirtane, B.R. Guru, A.E. Grill, J. Whittum-Hudson, and J. Panyam Folic acid functionalized nanoparticles for enhanced oral drug delivery Mol. Pharm. 9 2012 2103 2110
3. S.K. Singh, V.T. Banala, G.K. Gupta, A. Verma, R. Shukla, V.K. Pawar, P. Tripathi, and P.R. Mishra Development of docetaxel nanocapsules for improving in vitro cytotoxicity and cellular uptake in MCF-7 cells Drug Dev. Ind. Pharm. 2015 1 10
4. M. Malingré, J. Beijnen, and J.M. Schellens Oral delivery of taxanes Invest. New Drugs 19 2001 155 162
5. A. Sparreboom, J. van Asperen, U. Mayer, A.H. Schinkel, J.W. Smit, D.K. Meijer, P. Borst, W.J. Nooijen, J.H. Beijnen, and O. van Tellingen Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc. Natl. Acad. Sci. U.S.A. 94 1997 2031 2035
6. T. Walle Assays of CYP2C8- and CYP3A4-mediated metabolism of taxol in vivo and in vitro Methods Enzymol. 272 1996 145 151
7. L. Mei, Z. Zhang, L. Zhao, L. Huang, X.L. Yang, J. Tang, and S.S. Feng Pharmaceutical nanotechnology for oral delivery of anticancer drugs Adv. Drug. Deliv. Rev. 65 2013 880 890
8. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598
9. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23 2005 7794 7803
10. N.K. Ibrahim, B. Samuels, R. Page, D. Doval, K.M. Patel, S.C. Rao, M.K. Nair, P. Bhar, N. Desai, and G.N. Hortobagyi Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J. Clin. Oncol. 23 2005 6019 6026
11. Z. Zhang, and S.S. Feng Self-assembled nanoparticles of poly(lactide)-Vitamin E TPGS copolymers for oral chemotherapy Int. J. Pharm. 324 2006 191 198
12. S. Khandavilli, and R. Panchagnula Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats J. Invest. Dermatol. 127 2007 154 162
13. S. Peltier, J.M. Oger, F. Lagarce, W. Couet, and J.P. Benoit Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules Pharm. Res. 23 2006 1243 1250
14. K. Thanki, R.P. Gangwal, A.T. Sangamwar, and S. Jain Oral delivery of anticancer drugs: challenges and opportunities J. Control Release 170 2013 15 40
15. V.B. Junyaprasert, and B. Morakul Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs Asian J. Pharm. Sci. 10 2015 13 23
16. L. Gao, G. Liu, J. Ma, X. Wang, L. Zhou, X. Li, and F. Wang Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs Pharm. Res. 30 2013 307 324
17. V.K. Pawar, Y. Singh, J.G. Meher, S. Gupta, and M.K. Chourasia Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery J. Control Release 183 2014 51 66
18. R. Shegokar, and R.H. Müller Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives Int. J. Pharm. 399 2010 129 139
19. L. Gao, G. Liu, J. Kang, M. Niu, Z. Wang, H. Wang, J. Ma, and X. Wang Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies Colloids Surf. B 111 2013 277 281
20. K. Fuhrmann, J.D. Schulz, M.A. Gauthier, and J.-C. Leroux PEG nanocages as non-sheddable stabilizers for drug nanocrystals ACS Nano 6 2012 1667 1676
21. S. Sharma, A. Verma, B.V. Teja, P. Shukla, and P.R. Mishra Development of stabilized Paclitaxel nanocrystals: In-vitro and in-vivo efficacy studies Eur. J. Pharm. Sci. 69 2015 51 60
22. W. Sun, W. Tian, Y. Zhang, J. He, S. Mao, and L. Fang Effect of novel stabilizers-cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals Nanomedicine 8 2012 460 467
23. P. Venkataraman, J. Tang, E. Frenkel, G.L. McPherson, J. He, S.R. Raghavan, V. Kolesnichenko, A. Bose, and V.T. John Attachment of a hydrophobically modified biopolymer at the oil-water interface in the treatment of oil spills ACS Appl. Mater. Interfaces 5 2013 3572 3580
24. P.R. Mishra, L. Al Shaal, R.H. Muller, and C.M. Keck Production and characterization of Hesperetin nanosuspensions for dermal delivery Int. J. Pharm. 371 2009 182 189
25. K.C. Remant Bahadur, S. Aryal, S.R. Bhattarai, N. Bhattarai, C.H. Kim, and H.Y. Kim Stabilization of gold nanoparticles by hydrophobically-modified polycations J. Biomater. Sci. Polym. Ed. 17 2006 579 589
26. O. Carrier, R. Covis, E. Marie, and A. Durand Inverse emulsions stabilized by a hydrophobically modified polysaccharide Carbohydr. Polym. 84 2011 599 604
27. S.R. Bhattarai, S.Y. Kim, K.Y. Jang, K.C. Lee, H.K. Yi, D.Y. Lee, H.Y. Kim, and P.H. Hwang N-hexanoyl chitosan-stabilized magnetic nanoparticles: enhancement of adenoviral-mediated gene expression both in vitro and in vivo Nanomedicine 4 2008 146 154
28. H.-W. Sung, K. Sonaje, Z.-X. Liao, L.-W. Hsu, and E.-Y. Chuang PH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications Acc. Chem. Res. 45 2012 619 629
29. D. Chen, D. Xia, X. Li, Q. Zhu, H. Yu, C. Zhu, and Y. Gan Comparative study of Pluronic((R)) F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats Int. J. Pharm. 449 2013 1 9
30. Y. Guan, J. Huang, L. Zuo, J. Xu, L. Si, J. Qiu, and G. Li Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism Arch. Pharm. Res. 34 2011 1719 1728
31. G. Battogtokh, and Y. Ko Self-assembled chitosan-ceramide nanoparticle for enhanced oral delivery of Paclitaxel Pharm. Res. 2014 1 12
32. E. Lee, J. Lee, I.H. Lee, M. Yu, H. Kim, S.Y. Chae, and S. Jon Conjugated chitosan as a novel platform for oral delivery of Paclitaxel J. Med. Chem. 51 2008 6442 6449
33. D. Chen, D. Xia, X. Li, Q. Zhu, H. Yu, C. Zhu, and Y. Gan Comparative study of Pluronic® F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats Int. J. Pharm. 449 2013 1 9
34. R. Mo, X. Jin, N. Li, C. Ju, M. Sun, C. Zhang, and Q. Ping The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles Biomaterials 32 2011 4609 4620
35. K.M. Park, S.Y. Lee, Y.K. Joung, J.S. Na, M.C. Lee, and K.D. Park Thermosensitive chitosan-pluronic hydrogel as an injectable cell delivery carrier for cartilage regeneration Acta Biomater. 5 2009 1956 1965
36. F.Q. Hu, L.N. Liu, Y.Z. Du, and H. Yuan Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles Biomaterials 30 2009 6955 6963
37. P. Ramalingam, and Y.T. Ko Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations Pharm. Res. 32 2015 389 402
38. Y.Y. Zhou, Y.Z. Du, L. Wang, H. Yuan, J.P. Zhou, and F.Q. Hu Preparation and pharmacodynamics of stearic acid and poly (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles for 10-hydroxycamptothecin Int. J. Pharm. 393 2010 143 151
39. M. Malhotra, C. Tomaro-Duchesneau, S. Saha, I. Kahouli, and S. Prakash Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA Int. J. Nanomed. 8 2013 2041 2052
40. E. Roger, F. Lagarce, and J.P. Benoit The gastrointestinal stability of lipid nanocapsules Int. J. Pharm. 379 2009 260 265
41. S. Jain, D. Kumar, N.K. Swarnakar, and K. Thanki Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel Biomaterials 33 2012 6758 6768
42. Y. Ge, Y. Zhang, S. He, F. Nie, G. Teng, and N. Gu Fluorescence modified chitosan-coated magnetic nanoparticles for high-efficient cellular imaging Nanoscale Res. Lett. 4 2009 287 295
43. W. Zhang, K. Gilstrap, L. Wu, K.C. Remant Bahadur, M.A. Moss, Q. Wang, X. Lu, and X. He Synthesis and characterization of thermally responsive pluronic F127-chitosan nanocapsules for controlled release and intracellular delivery of small molecules ACS Nano 4 2010 6747 6759
44. M. Troutman, and D. Thakker Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in caco-2 cells Pharm. Res. 20 2003 1192 1199
45. A. Nandy, S.K. Dey, S. Das, R.N. Munda, J. Dinda, and K.D. Saha Gold (I) N-heterocyclic carbene complex inhibits mouse melanoma growth by p53 upregulation Mol. Cancer 13 2014 1476 4598
46. Y.I. Chung, J.C. Kim, Y.H. Kim, G. Tae, S.Y. Lee, K. Kim, and I.C. Kwon The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting J. Control Release 143 2010 374 382
47. S. Sharma, A. Verma, B.V. Teja, P. Shukla, and P.R. Mishra Development of stabilized Paclitaxel nanocrystals: In-vitro and in-vivo efficacy studies Eur. J. Pharm. Sci. 2 2015 51 60
48. L. Gao, D. Zhang, M. Chen, T. Zheng, and S. Wang Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement Drug Dev. Ind. Pharm. 33 2007 1332 1339
49. J. Pardeike, D.M. Strohmeier, N. Schrodl, C. Voura, M. Gruber, J.G. Khinast, and A. Zimmer Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines Int. J. Pharm. 420 2011 93 100
50. Y. Li, Z. Wu, W. He, C. Qin, J. Yao, J. Zhou, and L. Yin Globular protein-coated Paclitaxel nanosuspensions: interaction mechanism, direct cytosolic delivery, and significant improvement in pharmacokinetics Mol. Pharm. 12 2015 1485 1500
51. J. Rejman, V. Oberle, I.S. Zuhorn, and D. Hoekstra Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis Biochem. J. 377 2004 159 169
52. A. Siew, H. Le, M. Thiovolet, P. Gellert, A. Schatzlein, and I. Uchegbu Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharm. 9 2012 14 28
53. K. Sonaje, E.Y. Chuang, K.J. Lin, T.C. Yen, F.Y. Su, M.T. Tseng, and H.W. Sung Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations Mol. Pharm. 9 2012 1271 1279
54. A.M. Sadeghi, F.A. Dorkoosh, M.R. Avadi, M. Weinhold, A. Bayat, F. Delie, R. Gurny, B. Larijani, M. Rafiee-Tehrani, and H.E. Junginger Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells Eur. J. Pharm. Biopharm. 70 2008 270 278
55. L. Casettari, D. Vllasaliu, G. Mantovani, S.M. Howdle, S. Stolnik, and L. Illum Effect of PEGylation on the toxicity and permeability enhancement of chitosan Biomacromolecules 11 2010 2854 2865
56. J. Zastre, J. Jackson, M. Bajwa, R. Liggins, F. Iqbal, and H. Burt Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by caco-2 cells using low molecular weight methoxypolyethylene glycol-block-polycaprolactone diblock copolymers Eur. J. Pharm. Biopharm. 54 2002 299 309
57. E. Roger, F. Lagarce, E. Garcion, and J.P. Benoit Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery Nanomedicine 5 2010 287 306
58. X. Huang, X. Teng, D. Chen, F. Tang, and J. He The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function Biomaterials 31 2010 438 448
59. S. Barua, J.-W. Yoo, P. Kolhar, A. Wakankar, Y.R. Gokarn, and S. Mitragotri Particle shape enhances specificity of antibody-displaying nanoparticles Proc. Natl. Acad. Sci. 110 2013 3270 3275
60. B. Sarmento, S. Martins, D. Ferreira, and E.B. Souto Oral insulin delivery by means of solid lipid nanoparticles Int. J. Nanomed. 2 2007 743 749
61. P. Jani, G.W. Halbert, J. Langridge, and A.T. Florence Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency J. Pharm. Pharmacol. 42 1990 821 826
62. Z.G. Yue, W. Wei, P.P. Lv, H. Yue, L.Y. Wang, Z.G. Su, and G.H. Ma Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles Biomacromolecules 12 2011 2440 2446
63. Z.-G. Yue, W. Wei, P.-P. Lv, H. Yue, L.-Y. Wang, Z.-G. Su, and G.-H. Ma Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles Biomacromolecules 12 2011 2440 2446
64. K. Kostarelos, L. Lacerda, G. Pastorin, W. Wu, Sebastien Wieckowski, J. Luangsivilay, S. Godefroy, D. Pantarotto, J.-P. Briand, S. Muller, M. Prato, and A. Bianco Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type Nat. Nano 2 2007 108 113
65. D. Pantarotto, R. Singh, D. McCarthy, M. Erhardt, J.P. Briand, M. Prato, K. Kostarelos, and A. Bianco Functionalized carbon nanotubes for plasmid DNA gene delivery Angew. Chem. Int. Ed. Engl. 43 2004 5242 5246
66. N.G. Schipper, S. Olsson, J.A. Hoogstraate, A.G. deBoer, K.M. Varum, and P. Artursson Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement Pharm. Res. 14 1997 923 929
67. S.M. van der Merwe, J.C. Verhoef, J.H.M. Verheijden, A.F. Kotzé, and H.E. Junginger Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs Eur. J. Pharm. Biopharm. 58 2004 225 235
68. J.S. Woo, C.H. Lee, C.K. Shim, and S.J. Hwang Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031 Pharm. Res. 20 2003 24 30
69. H.A. Bardelmeijer, M. Ouwehand, J.H. Beijnen, J.H. Schellens, and O. van Tellingen Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice Invest. New Drugs 22 2004 219 229
70. Y. Zhang, H. Li, H. Wang, F. Su, R. Qu, D. Yin, J. Dai, Y. Li, and X. Chen Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action Cancer Chemother. Pharmacol. 66 2010 851 859
71. H.A. Bardelmeijer, J.H. Beijnen, K.R. Brouwer, H. Rosing, W.J. Nooijen, J.H. Schellens, and O. van Tellingen Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein Clin. Cancer Res. 6 2000 4416 4421
72. M. Li, L. Si, H. Pan, A.K. Rabba, F. Yan, J. Qiu, and G. Li Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion Int. J. Pharm. 403 2011 37 45